http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S5677226-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a98cb1b197f761c87cd3caf32bc247e2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate | 1979-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76736063d1578c38e1e0bd7537ea3974 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_064bd7ebb1a2490902e5e17995f5ab83 |
| publicationDate | 1981-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S5677226-A |
| titleOfInvention | Antitumorigenic agent |
| abstract | PURPOSE: An antitumorigenic agent that contains a 5-fluoropyrimidine, thus showing increased antitumorigenic activity and reduced toxicity. n CONSTITUTION: The antitumorigenic agent contains a 5-fluoropyrimidine selected from 5'-deoxy-5-fluorouridine or 5'-deoxy-5-fluorocytidine and a uracyl selected from uracil, thymine and thymidine, preferably at a ratio of 1mol of the former to 0.5mol or more of the latter. A uracil itself does not show antitumorigenic effect, however, the addition of this compound remarkably increases the antitumorigenic effect of 5-fluoropyrimidine (6 times in an example). Further, no acute toxicity is observed even when the maximum dose that is technically possible in an experiment is administered. n COPYRIGHT: (C)1981,JPO&Japio |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6114520-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6211166-B1 |
| priorityDate | 1979-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.